ARVO 2023: YOSEMITE and RHINE trials compare faricimab to aflibercept
Roger Goldberg, MD, MBA, spoke with Ophthalmology Times® to share insights about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept.
ARVO 2023: Michael Ip shares 5 year follow-up of the original SCORE2 dataset
Michael Ip, MD, highlighted the results of the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.
ARVO 2023: Geographic atrophy progression in the Phase 3 OAKS and DERBY trials
Allen Chiang, MD, discussed the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials with our team at the 2023 ARVO annual meeting.
ARVO 2023: Treatment research for GUCY2D associated Leber congenital amaurosis type 1
Christine Kay, MD, discussed research for the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting held in New Orleans.
ARVO 2023: Apellis presents research on visual function, imaging, and AI
Caroline Baumal, MD, spoke with our onsite team at the 2023 ARVO annual meeting to share more about Apellis' presentations focusing on visual function, imaging and artificial intelligence.
ARVO 2023: The value of holographic optical coherence tomography (OCT) and continued imaging research
Dierck Hillmann, PhD, was interviewed by our onsite team at the 2023 ARVO annual meeting where he shared research on holographic optical coherence tomography (OCT).
ARVO 2023: Insights at the annual meeting regarding non-viral gene therapy targeting ABCA4 retinopathies
Theresa Heath, MD, MBA, spoke with our onsite team at this year's ARVO annual meeting in New Orleans where she shared insights regarding Non-viral gene therapy targeting ABCA4 retinopathies.
ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301
Kiora Pharmaceuticals presented preliminary results for its investigational drug, KIO-301, a light-sensing small molecule designed to reactivate visual function of the eye in response to light.
ARVO 2023: Clearside Biomedical presents data on suprachoroidal injection delivery platform
The presentations highlighted the Clearside Biomedical’s efforts in suprachoroidal delivery of agents to the back of the eye.
ARVO 2023: Eyenuk CEO and founder, Kaushal Solanki shares EU update on EyeArt
Kaushal Solanki, PhD, CEO and founder of Eyenuk, shared news about the company's EyeArt AI, which is cleared by the FDA to detect diabetic retinopathy.
ARVO 2023: Research on epigenetic reprogramming to reverse aging and restore function to RGCs
Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.
ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression
Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).
ARVO 2023: Nanoscope Therapeutics presents data on MCO-010, an optogenetic therapy for vision restoration in advanced retinitis pigmentosa
Nanoscope Therapeutics Inc. presented key data at the ARVO 2023 annual meeting regarding their from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, which has received both orphan drug and fast track designations from the FDA.
ARVO 2023: Using retinal imaging for early detection of diabetic retinopathy in underserved communities
Edmund Arthur, OD, PhD, FAAO, shared how retinal imaging can be an important tool for early detection of diabetic retinopathy in underserved communities.
ARVO 2023: Ascidian Therapeutics shares insight on new gene therapy
Our team met with Jay Barth, MD, at the 2023 ARVO annual meeting, where he shared more about the work at Ascidian Therapeutics and how the company is developing a new method to administer gene therapy.
ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting
D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease
Belite Bio Inc. presented 18-month data from its ongoing two-year, open-label Phase 2 clinical study of LBS-008 (Tinlarebant), a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA.
ARVO 2023: Data suggest greater retinal drying via faricimab when compared to aflibercept in wet AMD, DME
Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.
ARVO 2023: Valitor’s Presentation at ARVO 2023 details preclinical Data on its Anti-VEGF biologic in development for durable treatment of wet AMD
VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.
ARVO 2023: Atsena Therapeutics shares latest safety and efficacy data on possible gene therapy for GUCY2D-associated Leber congenital amaurosis (LCA1)
Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, a gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).
ARVO 2023: Carl Danzig, MD, FASRS shares new data on vision loss from the GATHER clinical program
Ophthalmology Times® spoke with Carl Danzig, MD, FASRS, at the 2023 ARVO annual meeting to learn more about the post hoc analysis for the GATHER trials and the new data on the correlation between vision loss and GA growth.
ARVO 2023: T. Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmology
At the 2023 ARVO annual meeting in New Orleans, our on-site team caught up with T. Y. Alvin Liu, MD, to discuss predictive AI and its application in ophthalmology and screening of the eyes.
ARVO 2023: Using donor tissue to identify the mechanism cell death of the RPE
Deborah Ferrington, PhD, spoke with on our on-site team at the 2023 ARVO annual meeting in New Orleans about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium (RPE).
ARVO 2023: Eyevensys reports data on EYS809 as treatment of wet AMD
Eyevensys reported data showing the efficacy and durability of EYS809, a dual-gene plasmid in development for the treatment of wet age-related macular degeneration (AMD).
ARVO 2023: Luxa Biotechnology shares progress of Phase 1/2a clinical trial for AMD treatment
At ARVO in New Orleans, Luxa Biotechnology shared an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD).
ARVO 2023: Association between visual impairment and neuropsychiatric symptoms of dementia
Researchers found in their analysis that visual impairment is associated with hallucinations, depression, agitation, and psychosis in patients with dementia, although, aging and comorbidities, among other factors, may be involved.
ARVO 2023: Optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and related dementias
Amir H. Kashani, MD, PhD, joined us to share insights from his presentation at the 2023 ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.
ARVO 2023: Nonclinical data by Adverum Biotechnologies regarding potential treatment of wet AMD
Adverum Biotechnologies Inc. shared nonclinical data at ARVO 2023 in New Orleans that staggered, bilateral administration of Ixo-vec in NHPs was well tolerated with encouraging therapeutic activity and no signals of increased inflammation.
ARVO 2023: Ocular blood flow and its relationship to acute coronary syndrome
The team of Japanese researchers found that the choroidal MBR in the nasal region is correlated with systemic arterial stiffness and is significantly lower in patients with coronary artery multivessel disease.
ARVO 2023: Hydrogen water intake improved RBF Dysregulation in response to flicker stimulation and systemic hyperoxia in type 2 diabetic mice
Hydrogen-rich water may have a place in treatment of retinal degeneration. The team of investigators found that the hydrogen-rich water significantly improved the retinal blood flow (RBF) dysregulation in type 2 diabetic mice.
2 Clarke Drive Cranbury, NJ 08512